Cytokinetics CYTK Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's operating cash flow?
- Cytokinetics (CYTK) reported operating cash flow of -$145.46M in Q1 2026.
- How has Cytokinetics's operating cash flow changed year-over-year?
- Cytokinetics's operating cash flow decreased by 10.5% year-over-year, from -$131.62M to -$145.46M.
- What is the long-term trend for Cytokinetics's operating cash flow?
- Over 4 years (2021 to 2025), Cytokinetics's operating cash flow has grown at a 37.5% compound annual growth rate (CAGR), from -$142.52M to -$510.01M.
- What does operating cash flow mean?
- The net cash flow resulting from the company's day-to-day business operations.
- How do you interpret operating cash flow?
- Positive values indicate the business is self-sustaining; negative values indicate a need for external financing.
- How does operating cash flow compare across companies?
- The most critical metric for assessing the financial health of pre-revenue or growth-stage biotech companies.